Bal Pharma share price, P/E, ROE & financials

On 6 Nov 2026, Bal Pharma was priced at ₹81.55, or 18.0× trailing earnings, against an industry P/E of 28.7×, and the shares are 35% below their 52-week high. It earns ROCE of 16% and ROE of 7.9%, and sales and net profit grew 0.1% and 35% a year over 3 years. Its dividend yield is 1.5%, and debt is 1.94× equity. It is a small-cap company with a market cap of ₹130 Cr, ranked 110th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 2.7% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹83.40
Day high: ₹83.40
Day low: ₹80.12
Prev. close: ₹83.56
Volume: 12.3K

Health check

1 good · 2 fair · 3 to check

ReturnsBehind
+2.7% over a year, better than 1 of 7 peers.
Price tagCheaper
P/E 18.0 vs industry 28.7.
GrowthSteady
Sales +0.1%, profit +34.7% a year over 3 years.
ProfitabilityAverage
ROCE 16.5% vs peer median 17.9%.
Balance sheetStretched
Debt 1.94× equity, interest covered 1.4×, Piotroski 6 of 9.
Red flags4 to check
Return on equity is low at 7.9%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹130 Cr, #110 of 154 in its industry by size.

Defensive

Beta 0.57 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹334 Cr · profit ₹7 Cr

Market cap: ₹130 Cr; Small cap
P/E: 18.0; Industry 28.7
Price to book: 1.58; Peers 4.99
Dividend yield: 1.47%
ROE: 7.9%; Peers 14.7%
ROCE: 16.5%; Peers 17.9%
Debt to equity: 1.94; Debt ₹160 Cr
EPS (TTM): ₹4.54; Face value ₹10
OPM (TTM): 10.1%; Net margin 2.2%
Sales growth: +34.5%; Latest quarter vs a year ago
Profit growth: +460.1%; Latest quarter vs a year ago
Price to sales: 0.39; EV/EBITDA 8.0

Strengths

Quarterly profit up 460.1% on a year ago.
Quarterly sales up 34.5% on a year ago.
P/E of 18.0 against an industry P/E of 28.7.

Risks to check

Return on equity is low at 7.9%.
Debt is 1.94× equity.
35% below its 52-week high.
Interest coverage of only 2.3×.

Derived automatically from reported figures. Not a recommendation.

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel…

Headquarters: Bengaluru
Employees: 939
Sector: Healthcare
ISIN: INE083D01012
Website: balpharma.com

Price range

52 weeks

₹60.00₹124.60

Today

₹80.12₹83.40

Avg volume (3M): 60.8K
1-year return: plus 2.7%
From 52-week high: minus 34.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
BALPHARMABal Pharma	81.55	minus 2.41%	130	18.0	1.58	16.5%	7.9%	10.1%	0.1%	34.7%	1.47%	plus 2.7%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
65.9	74	87.7	84.1	88.6
59.8	68.3	78.1	73.5	80.7
6.1	5.7	9.5	10.6	7.9
9.2%	7.7%	10.9%	12.6%	9.0%
0.7	1.1	0.3	−0.2	0.4
4.1	3.9	4.9	4.1	4.5
2.5	2.3	3.2	3.1	2.8
0.2	0.7	1.8	3.2	1.1
–	–	–	−12.0%	–
0.2	0.7	1.8	3.6	1.1
0.13	0.45	1.12	2.26	0.71

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +0.1%
Profit CAGR 3Y: +34.7%
EPS CAGR 3Y: +33.2%
ROE: 7.9%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
302	339	294	303
–	+12.4%	minus 13.2%	+3.0%
275	307	264	269
26.7	31.8	29.9	34
8.8%	9.4%	10.2%	11.2%
−2.4	1.7	−0.4	−2.2
10.5	14.5	14.5	14.9
9.1	10.1	9.8	11.1
0.1	0.1	0	0.1
4.7	9	5.1	5.9
44.8%	17.7%	−40.9%	−6.5%
2.6	7.4	7.2	6.3
–	+187.4%	minus 2.4%	minus 12.9%
1.67	4.96	4.56	3.95

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
15.7	15.8	15.9	15.9
48.1	56.2	61.5	66.3
133	142	150	167
116	106	108	127
313	320	336	376
64.2	67	75.4	85.2
2	2.6	4.4	8.5
1.4	0.3	4.2	5.2
7.5	19.9	10.4	9.2
238	230	241	267
313	320	336	376

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
−1.5	22.8	20.3	30.8
−22.2	−18.9	−14.9	−20.7
24.1	−1.2	−7.8	−9.6
0.4	2.7	−2.4	0.5
−14.6	−11	−18.8	−22.4
−16.2	11.8	1.5	8.5
−1.6	−1.6	−1.9	−1.9

Shareholding pattern

Source: NSE filings

50.9%

promoters

Promoters50.86%
Public49.14%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	50.86%	49.14%	0.00
30 Jun 2026	50.86%	49.14%	0.00
31 Mar 2026	50.86%	49.14%	0.00
31 Dec 2025	50.86%	49.14%	0.00
30 Sep 2025	50.86%	49.14%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you